organization · Reporting owner
Column Group IV GP, LP
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | 10% owner | September 03, 2026 | September 08, 2026 |
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | 10% owner | April 05, 2024 | April 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
Jointly reported with Column Group IV-A, LP, Column Group IV, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,200 |
Reported balance
After 2026-09-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-03 · Purchase · Acquired 89,200 · Balance 89,200 F1: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: The securities are directly held by Peter Svennilson. |
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group IV, LP | 4,312,139 |
Reported balance
Holding disclosure · report date 2026-09-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,312,139 F3: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to securities directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group IV-A, LP | 148,840 |
Reported balance
Holding disclosure · report date 2026-09-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 148,840 F4: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to securities directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy The Column Group Opportunity III, LP | 1,319,164 |
Reported balance
Holding disclosure · report date 2026-09-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,319,164 F5: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2: The securities are directly held by Peter Svennilson.
F3: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to securities directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
F4: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to securities directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
F5: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Jointly reported with COLUMN GROUP GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III GP, LP, Column Group IV, LP, Column Group IV-A, LP, TCG IV GP, LLC, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,000 |
Reported balance
After 2024-04-05 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)
F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.
F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)
F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F15: The securities were owned solely by Tim Kutzkey.
F16: The securities were directly held by Peter Svennilson.
F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RAPT Therapeutics, Inc.
Report date December 23, 2024 · Filed December 23, 2024
Jointly reported with COLUMN GROUP II, LP, Column Group IV, LP, Column Group IV-A, LP, TCG IV GP, LLC
Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2024-12-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-12-23 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,236,261 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,236,261 F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 42,189 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,189 F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 163 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 163 F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 145,401 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 145,401 F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,352,008 |
Reported balance
After 2024-12-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 1,599,417 |
Reported balance
After 2024-12-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.
F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:33 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 89,200 | $11.56 | $1,031,044.96 |
DisclosureSEC source: 0001193125-26-385268 · ownership.xml · nonDerivative · entry 1 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 89,200 F1 · price: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by Peter Svennilson. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries D Preferred Stock · Derivative | 5,133,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 17 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 0 Underlying: Common Stock · 688,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C-1 Preferred Stock · Derivative | 28,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 16 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 3,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C-1 Preferred Stock · Derivative | 827,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 15 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 110,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 357,216 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 14 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 47,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 10,467,526 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 13 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 1,403,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A Preferred Stock · Derivative | 330,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 12 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 44,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A Preferred Stock · Derivative | 9,670,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 11 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 1,296,629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 630,881 | $18.00 | $11,355,858.00 |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 10 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 1,319,164 F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 49,556 | $18.00 | $892,008.00 |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 9 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 148,840 F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 1,437,323 | $18.00 | $25,871,814.00 |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 8 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 4,312,139 F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 688,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 7 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 688,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 3,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 6 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 99,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 47,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 5 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 95,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 44,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 4 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 47,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 110,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 3 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 2,874,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 1,403,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 2 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 2,763,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:19 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 1,296,629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 1 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 1,360,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:59 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherWarrant (right to purchase) · Derivative | 1,599,417 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-139755 · ownership.xml · derivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,599,417 Underlying: Common Stock · 1,599,417 shares Expires not disclosed F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:59 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherWarrant (right to purchase) · Derivative | 1,352,008 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-139755 · ownership.xml · derivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,352,008 Underlying: Common Stock · 1,352,008 shares Expires not disclosed F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:59 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 1,599,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-139755 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 17:59 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | OtherCommon Stock | 1,352,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-139755 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | OtherCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 14 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,000 F17 · price: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. F17 · ownership.nature: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 44,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 13 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16 · ownership.nature: The securities were directly held by Peter Svennilson. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 12 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15 · ownership.nature: The securities were owned solely by Tim Kutzkey. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 11 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14 · ownership.nature: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 10 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13 · ownership.nature: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 1,298,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 9 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12 · ownership.nature: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 1,298,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 8 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11 · ownership.nature: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 2,265,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 7 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10 · ownership.nature: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 968,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 6 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9 · ownership.nature: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 858,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 5 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8 · ownership.nature: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 11,103,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 4 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7 · ownership.direct: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 90,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 3 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6 · ownership.nature: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 2,650,177 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 2 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5 · ownership.nature: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerCommon Stock | 949,862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 1 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3 · ownership.nature: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4 · ownership.nature: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 16:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 5,840 | $0.62 | $3,627.22 |
DisclosureSEC source: 0000950170-23-064854 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 949,862 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 16:30 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 16,791 | $0.71 | $11,879.63 |
DisclosureSEC source: 0000950170-23-064854 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 944,022 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 16:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 176,730 | $5.00 | $883,402.58 |
DisclosureSEC source: 0000899243-23-003137 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 927,231 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 7,542 | $5.00 | $37,706.98 |
DisclosureSEC source: 0000899243-23-003137 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 750,501 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.99 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 16:35 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 9,900 | $5.00 | $49,494.06 |
DisclosureSEC source: 0000899243-23-002637 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 742,959 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 16:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 500 | $5.00 | $2,498.00 |
DisclosureSEC source: 0000899243-23-002380 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 733,059 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 16:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 37,639 | $5.00 | $188,104.67 |
DisclosureSEC source: 0000899243-23-002380 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 732,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.975 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 16:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 5,378 | $4.95 | $26,602.81 |
DisclosureSEC source: 0000899243-23-001855 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 694,920 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 16:37 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 209,000 | $4.76 | $994,840.00 |
DisclosureSEC source: 0000899243-23-001695 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 689,542 F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 16:37 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 100,070 | $4.84 | $484,518.93 |
DisclosureSEC source: 0000899243-23-001695 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 480,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.70 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:29 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 300 | $4.98 | $1,493.01 |
DisclosureSEC source: 0000899243-22-038466 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 380,472 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.97 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 16:17 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 4,330 | $5.00 | $21,646.10 |
DisclosureSEC source: 0000899243-22-036916 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 380,172 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 16:17 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 35,997 | $5.00 | $179,941.80 |
DisclosureSEC source: 0000899243-22-036916 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 375,842 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 16:20 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 35,058 | $4.72 | $165,319.50 |
DisclosureSEC source: 0000899243-22-035277 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 339,845 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.30 to $4.99, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.